SCHEDULE 13G/A 0001178913-24-002709 0001496201 XXXXXXXX LIVE 1 American Depository Shares, each representing twenty (20) ordinary shares, no par value 03/31/2025 0001534248 Chemomab Therapeutics Ltd. 16385C104 Kiryat Atidim, Building 7 Tel Aviv L3 6158002 Rule 13d-1(c) Sphera Funds Management Ltd. b L3 0 900428 0 900428 900428 N 4.78 CO Percentage reported in Item 11 is based on 18,856,611 American Depositary Shares (''ADS'') outstanding as of December 31, 2024 (as reported in the Issuer's Annual Report on Form 20-F filed with the Securities and Exchange Commission (the ''SEC'') on April 4, 2025, which provides that 377,132,220 ordinary shares, no par value, were outstanding as of December 31, 2024. Each ADS represents 20 ordinary shares). Sphera Global Healthcare GP Ltd. b L3 0 900428 0 900428 900428 N 4.78 CO Percentage reported in Item 11 is based on 18,856,611 ADSs outstanding as of December 31, 2024 (as reported in the Issuer's Annual Report on Form 20-F filed with the SEC on April 4, 2025, which provides that 377,132,220 ordinary shares, no par value, were outstanding as of December 31, 2024. Each ADS represents 20 ordinary shares). Sphera Global Healthcare Management LP. b L3 0 900428 0 900428 900428 N 4.78 PN Percentage reported in Item 11 is based on 18,856,611 ADSs outstanding as of December 31, 2024 (as reported in the Issuer's Annual Report on Form 20-F filed with the SEC on April 4, 2025, which provides that 377,132,220 ordinary shares, no par value, were outstanding as of December 31, 2024. Each ADS represents 20 ordinary shares). Chemomab Therapeutics Ltd. Kiryat Atidim, Building 7, Tel Aviv, Israel, 6158002 Sphera Funds Management Ltd. Sphera Global Healthcare GP Ltd. Sphera Global Healthcare Management LP Address of the Principal Business Office of each of the reporting persons is: 4 Itzhak Sade, Building A, 29th Floor, Tel Aviv 6777504, Israel Each of the reporting person is organized under the laws of the State of Israel Y Incorporated by reference to Item 9 of the cover page of each reporting person. The securities reported herein by Sphera Funds Management Ltd., Sphera Global Healthcare GP Ltd. and Sphera Global Healthcare Management LP are beneficially owned as follows: (1) 900,428 ADSs, representing a total of 4.78% of the total ADSs outstanding, are held directly by Sphera Biotech Master Fund, which has delegated its investment management authority to Sphera Global Healthcare Management LP (the "Management Company"). Each ADS represents 20 ordinary shares of the Issuer. Note that the CUSIP number provided herein applies to the ADSs of the Issuer. No CUSIP number exists for the underlying ordinary shares. The Management Company is managed, controlled and operated by its general partner, Sphera Global Healthcare GP Ltd., the shares of which are owned 90% by Sphera Funds Management Ltd. This Statement shall not be construed as an admission by any of the reporting persons that it is the beneficial owner of any of the securities covered by this statement, and each reporting person disclaims beneficial ownership of any such securities. In addition, the reporting persons and other entities named in this Schedule 13G may be deemed to constitute a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that a group exists for purposes of Section 13(d) of the Securities Exchange Act of 1934 or for any other purpose, and each of the reporting persons and other entities named in this Schedule 13G disclaims the existence of any such group. Incorporated by reference to Item 11 of the cover page for each reporting person. Percentage reported in Item 11 for each reporting person is based on 18,856,611 ADSs outstanding as of December 31, 2024 (as reported in the Issuer's Annual Report on Form 20-F filed with the SEC on April 4, 2025, which provides that 377,132,220 ordinary shares, no par value, were outstanding as of December 31, 2024. Each ADS represents 20 ordinary shares). See row 5 of cover page of each reporting person See row 6 of cover page of each reporting person and note in Item 4(a) above See row 7 of cover page of each reporting person See row 8 of cover page of each reporting person and note in Item 4(a) above N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 1 Joint Filing Agreement by and among the Reporting Persons (incorporated herein by reference to Exhibit 1 to the Schedule 13G filed on August 20, 2024). https://www.sec.gov/Archives/edgar/data/1496201/000117891324002709/exhibit_1.htm Sphera Funds Management Ltd. /s/ Adi Hanetz 04/10/2025 Sphera Global Healthcare GP Ltd. /s/ Adi Hanetz 04/10/2025 Sphera Global Healthcare Management LP. /s/ Adi Hanetz 04/10/2025